Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

D Tracey, L Klareskog, EH Sasso, JG Salfeld… - Pharmacology & …, 2008 - Elsevier
During the past 30 years, elucidation of the pathogenesis of rheumatoid arthritis, Crohn's
disease, psoriasis, psoriatic arthritis and ankylosing spondylitis at the cellular and molecular …

Adalimumab for long‐term treatment of psoriatic arthritis: forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial

…, PA Ory, RJ Perdok, EH Sasso - … : Official Journal of …, 2007 - Wiley Online Library
Objective To evaluate the efficacy and safety of treatment with adalimumab, a fully human
anti–tumor necrosis factor (anti‐TNF) monoclonal antibody, over 48 weeks in patients with …

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

…, L Xiong, DK Hanzatian, J Salfeld, EH Sasso - Clinical …, 2009 - Elsevier
The TNF antagonists adalimumab, infliximab, and etanercept are effective treatments for
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, but only …

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.

…, MA Weinberg, J Medich, EH Sasso… - The Journal of …, 2007 - jrheum.org
OBJECTIVE: To demonstrate the safety and efficacy of adalimumab for the treatment of
active psoriatic arthritis (PsA) in patients with an inadequate response to disease modifying …

Human IgA and IgG F (ab') 2 that bind to staphylococcal protein A belong to the VHIII subgroup.

EH Sasso, GJ Silverman, M Mannik - Journal of immunology …, 1991 - journals.aai.org
Staphylococcal protein A (SPA) is a bacterial membrane protein that possesses, in addition
to its Fc gamma-binding activity, a distinct specificity for the Fab region of some IgM, IgA, IgG, …

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension …

…, K Papp, Y Poulin, Y Gu, S Rozzo, EH Sasso - Journal of the American …, 2012 - Elsevier
BACKGROUND: REVEAL was a 52-week phase III trial of adalimumab therapy for
moderate to severe chronic plaque psoriasis. Patients from REVEAL could enter an open-label …

Human IgM molecules that bind staphylococcal protein A contain VHIII H chains.

EH Sasso, GJ Silverman, M Mannik - Journal of immunology …, 1989 - journals.aai.org
Staphylococcal protein A (SPA) is a bacterial membrane protein which has distinct binding
sites for Fc gamma and for the Fab region of some IgM, IgG, IgA, and IgE molecules. This …

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial

…, S Saevarsdottir, SE Cruickshank, EH Sasso… - Annals of the …, 2015 - ard.bmj.com
Objectives Prediction of radiographic progression (RP) in early rheumatoid arthritis (eRA)
would be very useful for optimal choice among available therapies. We evaluated a multi-…

[HTML][HTML] Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT

…, EHS Choy, CT Ritchlin, RJ Perdok, EH Sasso - Arthritis research & …, 2010 - Springer
Introduction To identify independent predictors of radiographic progression in psoriatic arthritis
(PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in …

Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number.

EH Sasso, T Johnson, TJ Kipps - The Journal of clinical …, 1996 - Am Soc Clin Investig
51p1 is an immunoglobulin VH gene that is frequently expressed in B cell chronic lymphocytic
leukemia and early in B cell ontogeny. The 51p1 gene locus is highly polymorphic, …